SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers Health
If you suffered losses exceeding $50,000 in Hims between April 29, 2025 and June 22, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hims & Hers Health, Inc. ('Hims' or the 'Company') (NYSE: HIMS) and reminds investors of the August 25, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) that Hims was engaged in the 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk;' (2) that, as a result, there was a substantial risk that the Company's collaboration with Novo Nordisk would be terminated; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
On June 23, 2025, Novo Nordisk announced that it was ending its partnership with Hims, stating that Hims 'has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk.' Novo Nordisk further stated 'the 'semaglutide' active pharmaceutical ingredients that are in the knock-off drugs sold by telehealth entities and compounding pharmacies' may contain 'unsafe and illicit foreign ingredients.'
On this news, Hims' stock price fell $22.24, or 34.6%, to close at $41.98 per share on June 23, 2025, thereby injuring investors.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Hims' conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Hims & Hers Health class action, go to www.faruqilaw.com/HIMS or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4c96193e-9e8a-4e5d-878a-3e41b441e24a
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Earnings Miss: BE Semiconductor Industries N.V. Missed EPS By 11% And Analysts Are Revising Their Forecasts
Last week, you might have seen that BE Semiconductor Industries N.V. (AMS:BESI) released its quarterly result to the market. The early response was not positive, with shares down 8.5% to €117 in the past week. It was not a great result overall. While revenues of €148m were in line with analyst predictions, earnings were less than expected, missing statutory estimates by 11% to hit €0.40 per share. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Taking into account the latest results, BE Semiconductor Industries' 19 analysts currently expect revenues in 2025 to be €612.9m, approximately in line with the last 12 months. Statutory earnings per share are expected to drop 13% to €1.87 in the same period. Before this earnings report, the analysts had been forecasting revenues of €632.8m and earnings per share (EPS) of €2.15 in 2025. From this we can that sentiment has definitely become more bearish after the latest results, leading to lower revenue forecasts and a substantial drop in earnings per share estimates. Check out our latest analysis for BE Semiconductor Industries The analysts made no major changes to their price target of €136, suggesting the downgrades are not expected to have a long-term impact on BE Semiconductor Industries' valuation. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. The most optimistic BE Semiconductor Industries analyst has a price target of €170 per share, while the most pessimistic values it at €100.00. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation. Of course, another way to look at these forecasts is to place them into context against the industry itself. The period to the end of 2025 brings more of the same, according to the analysts, with revenue forecast to display 3.6% growth on an annualised basis. That is in line with its 3.0% annual growth over the past five years. Compare this with the broader industry (in aggregate), which analyst estimates suggest will see revenues grow 8.4% annually. So although BE Semiconductor Industries is expected to maintain its revenue growth rate, it's forecast to grow slower than the wider industry. The Bottom Line The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for BE Semiconductor Industries. Unfortunately, they also downgraded their revenue estimates, and our data indicates underperformance compared to the wider industry. Even so, earnings per share are more important to the intrinsic value of the business. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates. Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple BE Semiconductor Industries analysts - going out to 2027, and you can see them free on our platform here. It is also worth noting that we have found 1 warning sign for BE Semiconductor Industries that you need to take into consideration. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
7 minutes ago
- Yahoo
Earnings Update: Julius Bär Gruppe AG (VTX:BAER) Just Reported Its Interim Results And Analysts Are Updating Their Forecasts
Julius Bär Gruppe AG (VTX:BAER) last week reported its latest interim results, which makes it a good time for investors to dive in and see if the business is performing in line with expectations. It was a credible result overall, with revenues of CHF1.9b and statutory earnings per share of CHF4.98 both in line with analyst estimates, showing that Julius Bär Gruppe is executing in line with expectations. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Julius Bär Gruppe after the latest results. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. After the latest results, the 13 analysts covering Julius Bär Gruppe are now predicting revenues of CHF3.88b in 2025. If met, this would reflect a credible 4.2% improvement in revenue compared to the last 12 months. Statutory earnings per share are forecast to drop 10% to CHF3.79 in the same period. Before this earnings report, the analysts had been forecasting revenues of CHF3.89b and earnings per share (EPS) of CHF4.03 in 2025. The analysts seem to have become a little more negative on the business after the latest results, given the minor downgrade to their earnings per share numbers for next year. See our latest analysis for Julius Bär Gruppe The consensus price target held steady at CHF60.91, with the analysts seemingly voting that their lower forecast earnings are not expected to lead to a lower stock price in the foreseeable future. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values Julius Bär Gruppe at CHF70.00 per share, while the most bearish prices it at CHF51.50. There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view. Of course, another way to look at these forecasts is to place them into context against the industry itself. For example, we noticed that Julius Bär Gruppe's rate of growth is expected to accelerate meaningfully, with revenues forecast to exhibit 8.6% growth to the end of 2025 on an annualised basis. That is well above its historical decline of 0.5% a year over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in the industry are forecast to see their revenue grow 5.0% per year. Not only are Julius Bär Gruppe's revenues expected to improve, it seems that the analysts are also expecting it to grow faster than the wider industry. The Bottom Line The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. The consensus price target held steady at CHF60.91, with the latest estimates not enough to have an impact on their price targets. Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Julius Bär Gruppe analysts - going out to 2027, and you can see them free on our platform here. Another thing to consider is whether management and directors have been buying or selling stock recently. We provide an overview of all open market stock trades for the last twelve months on our platform, here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
15 minutes ago
- Yahoo
GDEV Sends Cash Back to Investors with Special Payout
GDEV Inc. (NASDAQ:GDEV) is included among the 14 Stocks that Paid Special Dividends in 2025. A gaming enthusiast in front of a widescreen monitor, lost in the game. GDEV Inc. (NASDAQ:GDEV) is a gaming and entertainment holding company dedicated to expanding and developing its portfolio of game franchises across multiple genres and platforms. Through its subsidiaries— such as Nexters and Cubic Games— it aims to produce games that captivate and entertain millions of players over the long term. Its popular titles, including Hero Wars, Island Hoppers, and Pixel Gun 3D, have collectively surpassed 550 million downloads and generated $2.5 billion in global bookings. On February 21, GDEV Inc. (NASDAQ:GDEV) announced that its Board of Directors had approved a one-time special cash dividend of $3.31 per share. This payout represents roughly a 20% yield, based on the volume-weighted average share price over the previous 30 trading days. The special dividend, amounting to around $60 million in total, will be funded using profits the company has accumulated in recent years. It represents part of GDEV's total cash holdings, which stood at approximately $153 million as of the third quarter of 2024. While we acknowledge the potential of GDEV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
